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Elevated Soluble Fms-Like Tyrosine Kinase-1 and
Placental-Like Growth Factor Levels Are Associated With
Development and Mortality Risk in Heart Failure
Muhammad Hammadah, MD; Vasiliki V. Georgiopoulou, MD, MPH, PhD;
Andreas P. Kalogeropoulos, MD, MPH, PhD; Malory Weber, MBA; Xi Wang, MD, PhD;
Michael A. Samara, MD; Yuping Wu, PhD; Javed Butler, MD, MPH; W.H. Wilson Tang, MD
Background—Vascular endothelial dysfunction may play an important role in the progression of heart failure (HF). We
hypothesize that elevated levels of vascular markers, placental-like growth factor, and soluble Fms-like tyrosine kinase-1
(sFlt-1) are associated with adverse outcomes in patients with HF. We also assessed possible triggers of sFlt-1 elevation
in animal HF models.
Methods and Results—We measured plasma placental-like growth factor and sFlt-1 in 791 HF patients undergoing elective
coronary angiogram. Median (interquartile range) placental-like growth factor and sFlt-1 levels were 24 (20–29) and
382 (277–953) pg/mL, respectively. After 5 years of follow-up, and after using receiver operator characteristic curves to
determine optimal cutoffs, high levels of sFlt-1 (≥280 pg/mL; adjusted hazard ratio, 1.47; 95% confidence interval, 1.03–
2.09; P=0.035) but not placental-like growth factor (≥25 pg/mL; adjusted hazard ratio, 1.26; 95% confidence interval,
0.94–1.71, P=0.12) were associated with adverse cardiovascular outcomes. In addition, significant elevation of sFlt-1
levels was observed in left anterior descending artery ligation and transverse aortic constriction HF mouse models after 4
and 8 weeks of follow-up, suggesting vascular stress and ischemia as triggers for sFlt-1 elevation in HF.
Conclusions—Circulating sFlt-1 is generated as a result of myocardial injury and subsequent HF development. Elevated
levels of sFlt-1 are associated with adverse outcomes in stable patients with HF.  

P

lacental-like growth factor (PlGF), a member of the vascular endothelial growth factor (VEGF) family, and soluble
Fms-like tyrosine kinase-1 (sFlt-1) are vascular biomarkers
that were found to be involved in the preeclampsia process
and peripartum cardiomyopathy.1 PlGF stimulates endothelial
healing and recruitment of mononuclear bone marrow cells,
and thus, it has a role in stimulating microvascular angiogenesis.2 In contrast, sFlt-1 plays a counter-regulatory role by
sequestering and blocking circulating PlGF.3 Both markers
were found to be elevated in heart failure (HF), and higher
sFlt-1 has been associated with adverse clinical outcomes.4
Furthermore, in animal models, antagonizing VEGF by bevacizumab has been associated with development of HF.5 These
observations may imply that such vascular processes may be
mechanistically linked to HF disease progression. Therefore,
we aim to test the hypothesis that PlGF and sFlt-1 are associated with adverse outcomes in HF regardless of underlying
reduced or preserved ejection fraction (EF), and in distinct
but complementary animal HF models, that sFlt-1 generation
occurs independent of cardiac insult.

Methods
Study Population
A total of 791 subjects with HF were enrolled from Cleveland Clinic
GeneBank study, a large, prospective cohort study conducted between
2001 and 2007 that established a well-characterized clinical repository with clinical and longitudinal outcome data composed of consenting subjects undergoing an elective diagnostic cardiac catheterization
procedure. This analysis included 791 subjects with HF, out of 2000
patients, without evidence of myocardial infarction (MI, cardiac troponin I <0.03 ng/mL) and with plasma samples available for analysis.
The inclusion criteria included age older than 18 years, ability to understand and sign written informed consent to participate, and a diagnosis of HF with either reduced or preserved EF. Exclusion criteria
included congenital heart disease, previous heart transplant, known
cardiac infiltrative disease (eg, amyloidosis), previous other solid organ transplantation, and end-stage HF requiring outpatient continuous
inotrope infusion. Institutional review board approval was obtained,
and informed consent was signed by all subjects before enrollment.

Because difference between levels of vascular markers in HF
population and normal population is unknown, we have also enrolled
a group of 312 healthy young subjects to determine reference range
of vascular biomarkers.

sFlt-1 and PlGF Measurement and Patient Groupings
After informed consent, all patients had collection of blood samples at
baseline. Levels of sFlt-1 and PlGF were measured using investigational immunoassays on the Architect ci8200 platform in a research core
laboratory (Abbott Laboratories, Abbott Park, IL). B-type natriuretic
peptide (BNP) levels were also measured in the same samples using
the sample platform. Patients were grouped into those with high levels
of vascular markers (≥cutoff) and low levels (<cutoff). An estimate of
creatinine clearance was calculated using the Cockcroft–Gault equation. The presence of coronary artery disease was confirmed by luminal
stenosis of at least 70% in any major coronary artery. Left ventricular
EF was determined by the last best available data from clinical records
(echocardiography, radionucleotide imaging, or ventriculogram during
coronary angiography in order of preference). Adjudicated long-term
survival was ascertained for all subjects after enrollment. Mortality
data were collected through medical records review, information from
family members, and Social Security Death Index query.

Animal Models of HF
The Cleveland Clinic Institutional Animal Care and Use Committee
approved all animal studies. We assessed circulating sFlt-1 levels in
2 well-established rodent HF models representing cardiac insults
caused by acute MI (left anterior descending [LAD] coronary ligation) and by pressure overload (transverse aortic constriction [TAC]),
as previously described.6 For the LAD ligation model, the left atrium
was retracted for visualization of the proximal LAD using a surgical
microscope (Leica M500, Prescott’s Inc., Monument, CO) and the
LAD coronary artery was ligated with 10-0 prolene suture. For the
TAC model, midsternal incision was made to expose transverse aorta
between truncus anonymous and the left carotid artery. With 6-0 silk
suture, a ligature is tied around the transverse aorta against a 26-gauge
needle. Both HF models were performed in 12-week male C57BL/6J
mice, and plasma samples were collected by ventricular puncture at
the time of euthanize after 4 weeks postoperatively from LAD mice
(n=4) and TAC mice (n=4) and 8 weeks postoperatively from LAD
mice (n=3) and TAC mice (n=6). Plasma sFlt-1 was assayed using a
mouse assay (Quantikine ELISA, R&D Systems, Minneapolis, MN).

Statistical Analysis
The Student t test or Wilcoxon-rank sum test, for continuous variables,
and χ2 test for categorical variables were used to examine differences
between the groups. Survival and event rates were described with the
Kaplan–Meier method. Cox proportional hazards regression was used to
determine hazard ratios and 95% confidence intervals for 5-year survival.
In multivariable models, we adjusted for traditional cardiac risk factors,
including age, sex, race, log-transformed body mass index, diabetes
mellitus, systolic blood pressure, low-density lipoprotein, high-density
lipoprotein, calculated glomerular filtration rate, smoking, coronary artery disease and medications (angiotensin converting enzyme inhibitors,
β-blockers), and log-transformed EF. Analyses were also repeated after
adjustment for baseline log-transformed BNP and cardiac troponin I levels. Receiver operator characteristic curve analyses with 5-fold cross-validation were used to determine the optimal sFlt-1 and PlGF cutoffs. For a
given cutoff, we used a Cox model to estimate mortality risk. The 5-fold
cross-validation divides the data into 5 approximately equally sized portions. A Cox model is trained on 4 parts of the data and then estimates
the risk of mortality in the fifth part. This is repeated for each of the 5
parts. We calculated the area under the curve with the estimated risk.
This process is performed for a grid of sFlt-1 and PlGF cutoff values,
ranging from 105.6 to 21 044 pg/mL with an increment of 1 pg/mL for
sFlt-1 and ranging from 8.2 to 84.5 pg/mL with an increment of 0.5 pg/
mL for PlGF. The optimal cutoff is chosen to maximize area under the
curve values. We also used logistic regression to assess factors associated
with increased odds of having high levels of vascular markers (≥cutoffs).

Results
Baseline Patient Characteristics
Overall, a total of 791 patients with diagnosis of HF were
included in this study. The baseline characteristics of the study
population are presented in Table 1. Compared with the reference group of 312 healthy young subjects assessed by our
laboratory (mean age, 42±14 years; male. 41%; smoking, 7%;
Table I in the Data Supplement), and after adjustment for age,
sex, race, diabetes mellitus, hypertension, hyperlipidemia and
smoking, patients with HF had significantly higher levels of
sFlt-1 [median of 382 (277–955) versus 249 (226–276) pg/mL,
adjusted P=0.005] and PlGF [median of 24 (20–29) versus
15.5 (13.5–18) pg/mL, adjusted P<0.001; Figure 1].

Demographics Based on sFlt-1 Levels
Using area under the curve and 5-fold cross-validation as
described above, cutoff of 280 pg/mL for sFlt-1 and 25 pg/mL
for PlGF was found to maximize area under the curve for association with adverse outcomes. Table 1 showed demographics
based on high/low sFlt-1 levels using these cutoffs. Patient
with high sFlt-1 had significantly lower creatinine clearance
as well as higher BNP levels. Using multivariate logistic
regression analysis, we found decreased creatinine clearance
as well as increased BNP levels to be independent predictors
of high sFlt-1 and PlGF. Presence of coronary artery disease
was also found to be an independent predictor of high PlGF.

sFlt-1 and PlGF and Long-Term Survival in HF
Patients
After 5 years of follow-up, 228 (28.8%) of the patients reached
the primary outcome (all-cause mortality). High levels of
sFlt-1 and PlGF were significantly associated with higher rate
of adverse outcomes (Table 2). After adjustment for coronary
artery disease risk factors, medications, creatinine clearance,
EF, BNP, and cardiac troponin I, high sFlt-1 but not PlGF
remained an independent predictor of all-cause mortality with
hazard ratio (95% confidence interval) of 1.47 (1.03–2.09);
P=0.035 and 1.26 (0.94–1.71); P=0.12, respectively (Figure 2).
Subgroup analysis showed sFlt-1 to be associated with adverse
outcomes mainly in patients with EF >40% and patients with
coronary artery disease. However, there was no significant
interaction between sFlt-1 and EF. Similarly, no interaction
was found between PlGF and EF. We validated these results
on a group of 175 patients with predominantly, nonischemic
HF with low EF (coronary artery disease, 39%; EF, 26±14%)
enrolled from the Atlanta cardiomyopathy consortium (TACC)
with a mean follow-up of 3.5±1 years. In this group of patients,
only sFlt-1 but not PlGF showed significant association with
increased mortality risk (Figure I in the Data Supplement).

sFlt-1 in Animal Models of HF
Giving the results of subgroup analyses, where sFlt-1 was
mainly associated with adverse outcomes in patients with
preserved EF and coronary artery disease, we tried to further
investigate possible triggers of sFlt-1 release using animal
models. In comparison with control group animals (n=4; mean
sFlt-1=259.3 pg/mL), the MI animal models of HF showed significant elevation in sFlt-1 levels after 4 and 8 weeks of LAD

Table 1.

Baseline Characteristics Stratified By sFlt-1 Levels

Age, y

Total (n=791)

sFlt-1<280 pg/mL (n=210)

sFlt-1≥280 pg/mL (n=581)

P Value

66±11

67±10

66±11

0.805

Male, %

60

63

58

0.238

Black, %

4

2

5

0.139

70

72

69

0.548

40

0.294

Former/current smokers, %
Diabetes mellitus, %

41

Systolic blood pressure, mm Hg

45

128 (115–143)

132 (119–148)

127 (114–142)

0.011

28 (25–32)

29 (25–32)

28 (25–33)

0.593

82.1 (60–109)

85 (66–113)

81 (58–109)

0.03

LDL cholesterol, mg/dL

92 (73–113)

92 (78–116)

91 (71–112)

0.156

HDL cholesterol, mg/dL

31 (26–39)

32 (27–39)

31 (26–40)

0.197

Body mass index, kg/m2
Creatinine clearance, mL/min/1.73 m2

Coronary artery disease, %

76

81

75

0.117

Myocardial infarction, %

58

63

56

0.098

Atrial fibrillation, %

51

42

54

0.004

β-Blocker, %

67

71

66

0.145

ACE inhibitors or ARBs, %

68

73

66

0.039

Nitrates, %

39

41

39

0.542

ICD, %

10

8

11

0.258

CRT, %

1

0

1

0.087

B-type natriuretic peptide, pg/mL
Left ventricular ejection fraction, %

298 (119–647)

183 (84–424)

342 (147–792)

0.001

40 (25–55)

40 (30–55)

40 (25–55)

0.937

25 (21–31)

<0.001

PlGF, pg/mL

24 (20–29)

23 (19–26)

sFlt-1, pg/mL

382 (277–953)

241 (223–262)

Cardiac troponin I, ng/mL

0.009 (0.001–0.029)

0.007 (0–0.018)

588 (359–1459)
0.011 (0.001–0.038)

<0.001
0.003

ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blockers; CRT, cardiac resynchronization therapy; HDL, high-density lipoprotein; ICD,
implantable cardioverter defibrillator; LDL, low-density lipoprotein; PlGF, placental-like growth factor; and sFlt-1, soluble Fms-like tyrosine kinase-1.

artery ligation (Figure 3). Similar findings were found as well
in TAC models on 4 and 8 weeks after model design (Figure 3).

Discussion
There are several key observations. First, we demonstrate that
patients with HF have significantly higher circulating sFlt-1
and PlGF levels in comparison with normal healthy population and regardless of impaired or preserved left ventricular
EF. Increased levels of sFlt-1 were found to be associated with
worse renal function, although they still independently predicted poor long-term survival. Using different forms of cardiac
insult in animal models, we further demonstrated that elevated
sFlt-1 levels occur irrespective of the types of inciting cardiac
insults. Taken together, these observations imply that in patients
with stable HF, high sFlt-1 may be generated as a consequence
of the development and progression of HF. This may, in turn,
reflect the critical role of imbalance in myocardial angiogenesis
and the ventricular-arterial relationship in patients with HF.
Vascular markers were mainly studied in a preeclampsia
population where low/high levels of PlGF/sFlt-1, respectively,
were found to be associated with diffuse endothelial dysfunction and vascular rarefaction.1,3,4,7–9 Subsequently, protein urea,
increased blood pressure, and eclampsia could develop.10 High
sFlt-1 was also found to be associated with increased risk of
peripartum cardiomyopathy.1,7 Similarly, administration of
sFlt-1 in VEGF receptor depleted animals resulted in profound
dilated cardiomyopathy with significant decreased in capillary

density.1 However, intramyocardial provision of exogenous
VEGF in animal models for pressure overload (aortic banding)
has been shown to preserve coronary blood flow reserve and left
ventricular performance.11–13 However, there are limited reports
regarding the role of vascular markers in the pathogenesis and
disease progression of HF. Both PlGF and sFlt-1 were found to
be elevated after MI. High levels of PlGF were more in favor
of myocardial recovery, whereas high sFlt-1 levels were associated with increased risk of myocardial dysfunction.1,2,14–16 The
beneficial effect of exogenous PlGF in animal models post-MI
was neutralized by administration of sFlt-1.2 Similarly, use of
mimics to sFlt-1 (VEGF antagonists)-like bevacizumab was
found to be associated with increased risk of HF development.5,17 The prognostic value of circulating levels of vascular
markers has previously been reported in HF with impaired EF
(and largely nonischemic) patient population.4 In our observations from 2 separate cohorts, we have confirmed the association with adverse outcomes. Although, our subgroup analyses
revealed this association to be mainly driven by those with preserved EF and coronary artery disease, we did not find significant interaction between sFlt-1 and EF. Furthermore, sFlt-1 was
associated with adverse outcomes in TACC population (mainly
nonischemic HF with low EF). Taken together, with our animal
model findings, these results suggest the adverse association of
sFlt-1 and HF is independent of the insulting factor.
Interestingly, high levels of PlGF in our population also
showed unfavorable association with adverse outcomes.

Figure 1. Plasma levels of placental-like growth factor (PlGF, A) and soluble Fms-like tyrosine kinase-1 (sFlt-1, B) in patients with heart
failure (HF) stratified by impaired versus preserved left ventricular ejection fraction (LVEF) versus non-HF controls. Distribution of PlGF
(C) and sFlt-1 (D) in HF and non-HF population.

Similar findings were suggested before in Ky et al4 study.
Nakamura et al18 also found increased PlGF levels in patients
with increased HF severity in ischemic cardiomyopathy. In
contrary, reports from post-MI survivors showed favorable
cardiac recovery in those with high PlGF.2,15 This may suggest
Table 2.

protective role of PlGF in HF setting, and association with
adverse outcome might be related to increase cardiac severity
with a compensatory effort of the hypoxic tissue to overcome
the on-going microvascular ischemia. The beneficial effect of
PlGF/VEGF may be blocked and attenuated by high sFlt-1

Long-Term Mortality Using Vascular Markers
Soluble Fms-Like Tyrosine Kinase-1

Placental-Like Growth Factor

<280 pg/mL (n=210)

≥280 pg/mL (n=581)

P Value

<25 pg/mL (n=442)

≥25 pg/mL (n=349)

P Value

5-y death,* %

44/210=21.0%

184/581=31.7%

0.003

100/442=22.6%

128/349=36.7%

<0.001

Unadjusted HR

1

1.67 (1.21–2.31)

0.002

1

1.77 (1.36–2.30)

<0.001

Adjusted HR (model 1)

1

1.70 (1.20–2.41)

0.003

1

1.35 (1.00–1.81)

0.049

Adjusted HR (model 2)

1

1.48 (1.04–2.11)

0.029

1

1.29 (0.96–1.73)

0.093

Adjusted HR (model 3)

1

1.47 (1.03–2.09)

0.035

1

1.26 (0.94–1.71)

0.124

Model 1: adjusted for age, sex, race, logged body mass index, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, logtransformed creatinine clearance, diabetes mellitus, smoking, coronary artery disease, ACE inhibitors/ARBs, β-blockers, and log-transformed left ventricular ejection
fraction. Model 2: adjusted for model 1 plus B-type natriuretic peptide. Model 3: adjusted for model 2 plus cardiac troponin I. HR indicates hazard ratio.
*Kaplan–Meier percentages.

Figure 2. Kaplan–Meier curves and adjusted hazard ratio for association between vascular markers and all-cause mortality.

levels and other comorbidities that attenuate neovascular
response (eg, advance age, diabetes mellitus, increased oxidative stress, and hypertension).19
Despite we found that levels of sFlt-1 and PlGF are higher
in patients with HF compared with a normal healthy population, it is worth noting that the concentrations of vascular
markers are much lower than those reported during normal
pregnancy and in preeclampsia.20 In comparison with pregnancy where the placenta is the major trigger of the vascular
marker production,21 it is still unclear what the trigger is for
circulating sFlt-1 and PlGF production in the setting of HF.
Flt-1 is normally expressed on endothelial cells, and whether
cleavage of this receptor is done by an enzyme, ischemia,
or other stressors remains unclear. In our animal HF models, significant elevation in sFlt-1 was observed after both
the LAD ligation and TAC models, which suggests vascular stress, myocardial ischemia, or even sympathetic drive
may be possible triggers of sFlt-1 elevation. Indeed, previous reports found increased levels of sFlt-1 after MI.14–16
Furthermore, increased levels of sFlt-1 were found in patients
with resistant hypertension, and they were found to be associated with responders to renal denervation.22 These findings
together with our observation in animal models suggest that
any endothelial stressor may trigger increase sFlt-1 production and release.

Study Limitations
Despite being one of the largest HF cohorts reported with
vascular marker levels and long-term outcomes, our study has
some limitations. First, we do not have complete data about
cause of death, hospitalization, or consistent echocardiographic indices (like left ventricular hypertrophy or diastolic
indices) in all subjects. Second, we studied vascular markers at a single time point, and changes of vascular markers
or treatment responses need to be further explored. Third, the
Genebank study enrolled patients between 2001 and 2007, yet
new HF treatment modalities, like biventricular pacing and
aldosterone antagonist, were not commonly used. Whether
these treatment modalities have any effect on the association
between vascular markers and HF outcomes need to be further
investigated.

Conclusion
sFlt-1 may be released as a result of myocardial injury and
subsequent HF development. In high levels, sFlt-1 is associated with adverse outcomes in stable HF patients.
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